0001209191-20-055562.txt : 20201022 0001209191-20-055562.hdr.sgml : 20201022 20201022161209 ACCESSION NUMBER: 0001209191-20-055562 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201020 FILED AS OF DATE: 20201022 DATE AS OF CHANGE: 20201022 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wellington Biomedical Innovation Master Investors (Cayman) I L.P. CENTRAL INDEX KEY: 0001787092 STATE OF INCORPORATION: E9 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39617 FILM NUMBER: 201255042 BUSINESS ADDRESS: STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC STREET 2: 280 CONGRESS STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: (617) 951-5372 MAIL ADDRESS: STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC STREET 2: 280 CONGRESS STREET CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aligos Therapeutics, Inc. CENTRAL INDEX KEY: 0001799448 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (800) 466-6059 MAIL ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-20 1 0001799448 Aligos Therapeutics, Inc. ALGS 0001787092 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 0 0 1 0 Common Stock 2020-10-20 4 C 0 1335048 A 1335048 D Common Stock 2020-10-20 4 C 0 571143 A 1906191 D Series B-1 convertible Preferred Stock 2020-10-20 4 C 0 1335048 0.00 D Common Stock 1335048 0 D Series B-2 convertible Preferred Stock 2020-10-20 4 C 0 571143 0.00 D Common Stock 571143 0 D The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Alternative Investments, as General Partner, By: /s/ Peter N. McIsaac, Title: Managing Director & Counsel 2020-10-22